Skip to content

MDMA: all studies

Page 27 of 345: studies 261 to 270 of 3,446, newest first. Back to the MDMA overview

Research

MDMA("Ecstasy") abuse leading to delayed onset rhabdomyolysis: A case report and literature review.

Clinical Case Reports September 1, 2024 Swotantra Gautam, Aakash Neupane, Ivonne De La Hoz Molina et al. 1 citation

MDMA and cocaine can result in acute onset rhabdomyolysis. However, delayed onset rhabdomyolysis and its pathophysiology is of concern Early therapeutic intervention improves prognosis. Such cases should be promptly referred and managed in centers equipped with critical care and renal replacement therapy.

DOI: 10.1002/ccr3.9429 (opens in new tab) Full text (opens in new tab) Aki Creatine kinase Rhabdomyolysis MDMA Toxicity +3

Motives for MDMA Use: A Comparative Study with Alcohol and Cannabis

European Psychiatry August 27, 2024 Daniele Zullino, Louise Penzenstadler, Stéphane Rothen et al.

Introduction While research on drug use motives has primarily focused on widely used substances like alcohol, tobacco, and cannabis, understanding the motivations behind MDMA use is crucial for developing targeted therapeutic, preventive, and harm reduction strategies. Objectives The objective of this study is to present the findings of an online survey that evaluates the motives behind the use...

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

BMJ August 21, 2024 Trevor Thompson, Ping-Tao Tseng, Chih-Wei Hsu et al. 24 citations

Abstract Objective To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms, considering the potential for overestimated effectiveness due to unsuccessful blinding. Design Systematic review and Bayesian network meta-analysis. Data sources Medline, Cochrane Central Register of Controlled Trials,...

Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature.

Pharmaceutics August 20, 2024 Guillaume Drevin, Maria Pena-Martin, Aurélien Bauduin et al. 4 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative with notable psychoactive properties and emerging therapeutic potential, particularly for treating post-traumatic stress disorders (PTSD) and substance use disorders. However, its use remains controversial due to inter-individual variability influenced by both environmental and genetic factors. In this context,...

Stare substancje, nowe terapieczyli MDMA w terapii zaburzeń psychicznych

Kosmos August 8, 2024 Agnieszka Bysiek

3,4-Methyl​enedioxy​methamphetamine (MDMA) is a psychostimulant, which was synthesized for the first time in 1912 in Germany and later forgotten until the 1970s. Then due to its empathogenic and anti-anxiety qualities it was rediscovered as a psychotherapy adjunct, especially for patients requiring treatment for anxiety disorders and suffering after traumatic events. MDMA's positive effects and...

The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.

Archives of Toxicology August 1, 2024 Brian A Baldo 5 citations

The phenylethylamine, 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'), is the prototypical example of an entactogen. Its original placement in highly restrictive drug usage categories in the US and UK, led to an inevitable restriction on MDMA neuroscience research and treatment. The dominant pharmacological effects of MDMA are its properties of release and inhibition of reuptake of amine...

DOI: 10.1007/s00204-024-03765-8 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Ecstasy MDMA MDMA And PTSD MDMA Deaths +6

MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.

Contemporary Clinical Trials Communications August 1, 2024 Leslie A. Morland, Dimitri Perivoliotis, Tamara R Wachsman et al. 4 citations

Posttraumatic Stress Disorder (PTSD) impacts both individual and relational functioning. Veteran couples are at increased risk of relationship distress due to military stressors such as deployment, family reintegration, and traumatic stress. Although both Cognitive-Behavioral Conjoint Therapy (CBCT) and its brief version (bCBCT) consistently have large effects on reducing PTSD symptoms, these...

DOI: 10.1016/j.conctc.2024.101314 (opens in new tab) Full text (opens in new tab) MDMA Intimate relationships PTSD Treatment Couples therapy +3

MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?

The Senior Care Pharmacist July 31, 2024 Leigh Davitian 1 citation

In recent years, scientists have initiated a renaissance in psychedelic research following decades of prohibition. Compounds such as ketamine, LSD, and psilocybin 'once primarily associated with recreational use' are now being investigated for their therapeutic potential, with promising results. An estimated 40-60% of people with post-traumatic stress disorder (PTSD) do not respond to selective...

Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate”

Journal of Psychopharmacology July 28, 2024 Kurt Stocker, Matthias E. Liechti 15 citations

Science on methylenedioxymethamphetamine (MDMA) and MDMA-like substances is faced with the unique situation that this class of psychoactive agents is referred to with two basic names for its effects on the mind: empathogens and entactogens. Empathogen usually refers to the prosocial, empathetic, and openness properties of MDMA, while entactogen usually refers to the introspective and...

DOI: 10.1177/02698811241265352 (opens in new tab) MDMA Ecstasy Introspection Openness to experience +3